Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Diabetes Mellitus and Acute Coronary Syndrome: A Lethal Combination Requiring Better Therapeutic Strategies

Author(s): Niki Katsiki and Nikolaos Papanas*

Volume 18, Issue 1, 2020

Page: [77 - 79] Pages: 3

DOI: 10.2174/1570161117666190328095249

« Previous Next »
[1]
Shehab A, Bhagavathula AS, Al-Rasadi K, et al. Diabetes and mortality in acute coronary syndrome: Findings from the gulf coast registry. Curr Vasc Pharmacol 2020; 18(1): 68-76.
[2]
Norhammar A, Mellbin L, Cosentino F. Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. Eur J Prev Cardiol 2017; 24: 52-60.
[3]
El Ouazzani J, Ghalem A, El Ouazzani G, Ismaili N, El Ouafi N. Management of hyperglycemia during and in the immediate follow-up of acute coronary syndrome. J Saudi Heart Assoc 2018; 30: 113-21.
[4]
Franklin K, Goldberg RJ, Spencer F, et al. Implications of diabetes in patients with acute coronary syndromes. The global registry of acute coronary events. Arch Intern Med 2004; 164: 1457-63.
[5]
Wei CC, Shyu KG, Cheng JJ, Lo HM, Chiu CZ. Diabetes and adverse cardiovascular outcomes in patients with acute coronary syndrome - data from taiwan’s acute coronary syndrome full spectrum data registry. Acta Cardiol Sin 2016; 32: 31-8.
[6]
Shehab A, Al-Dabbagh B, Almahmeed W, et al. Characteristics, management, and in-hospital outcomes of diabetic patients with acute coronary syndrome in the United Arab Emirates. ScientificWorldJournal 2012; 2012698597
[7]
Alnemer KA, Alfaleh HF, Alhabib KF, et al. Impact of diabetes on hospital adverse cardiovascular outcomes in acute coronary syndrome patients: Data from the Saudi project of acute coronary events. J Saudi Heart Assoc 2012; 24: 225-31.
[8]
Meo SA, Usmani AM, Qalbani E. Prevalence of type 2 diabetes in the Arab world: Impact of GDP and energy consumption. Eur Rev Med Pharmacol Sci 2017; 21: 1303-12.
[9]
Sasso FC, Rinaldi L, Lascar N, et al. Role of tight glycemic control during acute coronary syndrome on cv outcome in type 2 diabetes. J Diabetes Res 2018; 20183106056
[10]
Chu CY, Lin TH, Lai WT. The management and prognostic factors of acute coronary syndrome: Evidence from the taiwan acute coronary syndrome full spectrum registry. Acta Cardiol Sin 2017; 33: 329-38.
[11]
Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2019. Diabetes Care 2019; 42: 90-102.
[12]
Tsioufis C, Tatsis I, Thomopoulos C, et al. Effects of hypertension, diabetes mellitus, obesity and other factors on kidney haemodynamics. Curr Vasc Pharmacol 2014; 12: 537-48.
[13]
Katsiki N, Fonseca V, Mikhailidis DP. Contrast-induced acute kidney injury in diabetes mellitus: Clinical relevance and predisposing factors. Could statins be of benefit? J Diabetes Complications 2018; 32: 982-4.
[14]
Katsiki N, Tsioufis C, Hahalis G, Athyros VG. Contrast-induced acute kidney injury: Beware of the risk after coronary angiography. Expert Rev Cardiovasc Ther 2018; 16: 73.
[15]
Uzunhasan I, Yildiz A, Arslan S, et al. Contrast-induced acute kidney injury is associated with long-term adverse events in patients with acute coronary syndrome. Angiology 2017; 68: 621-6.
[16]
Sun G, Chen P, Wang K, et al. Contrast-induced nephropathy and long-term mortality after percutaneous coronary intervention in patients with acute myocardial infarction. Angiology 2019; 70(7): 621-6.
[17]
Ali-Hasan-Al-Saegh S, Mirhosseini SJ, Ghodratipour Z, et al. Strategies preventing contrast-induced nephropathy after coronary angiography: a comprehensive meta-analysis and systematic review of 125 randomized controlled trials. Angiology 2017; 68: 389-413.
[18]
Yang SC, Fu NK, Zhang J, et al. preventive effects of alprostadil against contrast-induced nephropathy inpatients with renal insufficiency undergoing percutaneous coronary intervention. Angiology 2018; 69: 393-9.
[19]
Zhan B, Huang X, Jiang L, Bao H, Cheng X. effect of nicorandil administration on preventing contrast-induced nephropathy: A meta-analysis. Angiology 2018; 69: 568-73.
[20]
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Contrast-induced nephropathy: An “all or none” phenomenon? Angiology 2015; 66: 508-13.
[21]
Katsiki N, Triposkiadis F, Giannoukas AD, Mikhailidis DP. Statin loading in cardiovascular surgery: never too early to treat. Curr Opin Cardiol 2018; 33: 436-43.
[22]
O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: Executive summary: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. Circulation 2013; 127: 529-55.
[23]
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Atherosclerosis 2016; 253: 281-344.

Rights & Permissions Print Cite
Article Metrics
13
© 2024 Bentham Science Publishers | Privacy Policy